MRNA Price Prediction Next Week
Analysis and Insights
Technical Analysis:
Moderna's stock (MRNA) is currently trading at $34.51 as of 2025-03-17. Based on the technical indicators:
- RSI (14): 50.24, indicating a neutral position.
- MACD: -0.33, showing slight bearish momentum.
- Fibonacci Levels: Pivot at $33.80, with resistance at $37.15 and support at $30.45.
News Sentiment and Fundamental Analysis:
- Short Interest: Increased to 13.19%, making MRNA the most shorted stock in the healthcare sector.
- Financial Performance: Q4 2024 revenue dropped 65% year-over-year, with a wider-than-expected loss.
- Pipeline and Prospects: Strong cash position of $7 billion and a promising pipeline with potential approvals by 2027.
Conclusion:
Given the mixed technical indicators, increased short interest, and challenging market conditions for vaccine-focused companies, the stock is expected to face headwinds. However, the strong cash position and pipeline could provide support.
Prediction: MRNA stock is expected to trade between $32 and $35 next week, with a target price of $34. Considering the current technical and fundamental factors, a sell recommendation is suggested due to the bearish sentiment and short interest.
MRNA Similar Chart Price Prediction
The price of MRNA is predicted to go up 4.01%, based on the high correlation periods with OUST. The similarity of these two price pattern on the periods is 96.32%.
MRNA
OUST
Up: 4.01%Similarity: 96.32%
MRNA Revenue Forecast
MRNA EPS Forecast
MRNA FAQs
What is MRNA revenue forecast for next quarter？
What is MRNA eps forecast for next quarter？
MRNA VS S&P500
The stellar efficacy and safety profile of Moderna's COVID-19 vaccine offered rapid validation of the firm's mRNA technology.
Its mRNA technology could allow the firm to compete in a wide range of therapeutic areas, from other prophylactic vaccines (like influenza and other viruses) to enzyme replacement (various rare diseases) to cancer.
Moderna's cash infusion from COVID-19 vaccine sales in 2021-22, as well as newly established large-scale manufacturing facilities, position the firm to accelerate timelines for new pipeline programs.
MRNA Analyst's Forecast
Geoff Meacham
Citigroup
Hold
2025-03-13
Price Target
$40
Upside
+16.62%
Citi initiated coverage of Moderna with a Neutral rating and $40 price target. Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term "choppiness," a "barbell approach" to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi's preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are "clean growth stories." The firm highlights Apogee, Avidity, and Kymera as favorites.
Matthew Harrison
Morgan Stanley
Hold
2025-01-15
Price Target
$70 → $38
Upside
+9.29%
Eliana Merle
UBS
Strong Buy
2025-01-08
Price Target
$108 → $96
Upside
+127.22%
